The Illumina Complete Long Read Prep generates a simpler workflow with reduced DNA input requirements compared to other existing long-read offerings
The new long-read technology is available on the NovaSeq X Plus and NovaSeq X. (Credit: PRNewswire/Illumina, Inc.)
Array-based technologies provider Illumina has introduced Illumina Complete Long Read Prep, Human, the first product based on the company’s Illumina Complete Long Read technology.
The latest product is said to be a high-performance, long-read, human whole-genome sequencing (WGS) assay.
Illumina said that the assay is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems.
Illumina Complete Long Reads also grants access to long- as well as short-read data on the same Illumina instrument.
The product is said to enable a simpler workflow with reduced DNA input needs compared to other existing long-read offerings, the biotechnology firm claimed.
The WGS assay also offers an additional tool in the advancement of genetic disease testing as it enables access into hard-to-map areas with improved resolution and mapping.
Illumina said that the Complete Long Read Prep mixes Illumina sequencing by synthesis (SBS) chemistry with DRAGEN secondary analysis for delivering WGS with more accuracy.
The promotional price for customers is $1,350 per whole genome when using NovaSeq X Plus and a 25B flow cell.
Illumina CTO and research and product development head Alex Aravanis said: “Many long-read solutions have been stunted by high DNA input requirements, complex workflows with low throughput, and highly variable results on dedicated long-read instruments.
“Illumina Complete Long Reads overcomes those pain points and associated costs to make long-read sequencing accessible and streamlined for genomic labs.”
According to data presented by Aravanis in September 2022, Illumina Complete Long Reads with DRAGEN analysis showed an F1 score, a compound statistic of precision and recall of 99.87%.
Additionally, the shared data from early-access customers demonstrated the accuracy and flexible DNA input of Illumina Complete Long Reads. It also showed its ability to minimise cost and operational complexity.
Illumina intends to develop long-read applications using this technology as a foundation. The US-based biotechnology company will introduce an enrichment assay in the second half of 2023.